Infectious disease tests are one of the most dynamic spaces in the in vitro diagnostics (IVD) industry. Global market growth is a product of new disease threats as well as the introduction and clinical acceptance of routine screening procedures. The diversified market space promotes demand for novel diagnostic technologies such as PCR-alternative molecular amplification methods, next-generation sequencing (NGS), and mass spectrometry. The $17 billion+ global infectious disease diagnostics market also includes larger established segments in immunoassays and ID/AST.